TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in ...
Current protein engineering methods are inadequate to explore the combinatorial potential offered by nature’s vast repertoire of protein domains–limiting our ability to create optimal synthetic tools.
CHEYNEY, Pa., Sept. 13, 2021 /PRNewswire/ -- Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has entered into a Cooperative Research and Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results